Lantheus' Pylarify Hit $1B in 2024 Sales

Lantheus Holdings (LNTH -0.76%) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic transactions.Pylarify Achieves $1 Billion Sales MilestoneProstate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.We estimate [the addressable market] to be $2.5-plus billion in 2025 up from $2-plus billio ...